PTC's novel cystic fibrosis drug shows benefit in Phase IIa
This article was originally published in Scrip
PTC Therapeutics' PTC124, a novel investigational treatment for cystic fibrosis, is able to reduce the ion transport abnormalities seen in the condition, Phase IIa results suggest.
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
GlaxoSmithKlineand Xenoporthave submitted an NDA to the US FDAfor the once-daily restless legs syndrome drug Solzira (gabapentin enacarbil extended-release tablets), previously known as GSK1838262 by GSK and XP13512 by Xenoport.